TRAM34, also known as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole or CAS number 289905-88-0, is a selective inhibitor of intermediate-conductance calcium-activated potassium channels (IK channels). This product has been gaining attention from both scientists and pharmaceutical companies due to its potential health benefits. The chemical name of TRAM34 is 1-[2-(diphenylmethyl)phenyl]-(1H)-pyrazole.
Chemical name: The chemical name of TRAM34 is 1-[2-(diphenylmethyl)phenyl]-(1H)-pyrazole.
Molecular formula: The molecular formula of TRAM34 is C23H19ClN2.
Formula weight: The formula weight of TRAM34 is 358.86 g/mol.
CAS No: The CAS number of TRAM34 is 289905-88-0.
Top ten keywords from Google and Synonyms:
Synonyms: TRAM-34, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, N-(benzyloxycarbonyl)-L-leucine boronic acid.
Health benefits of this product: Several studies have suggested that TRAM34 may have several health benefits, including its ability to act as a selective inhibitor of IK channels, which can help treat various diseases such as immune system disorders, inflammation, and neurodegenerative diseases.
Potential effects: TRAM34 selectively inhibits the activity of IK channels, which play an essential role in regulating the calcium signaling and ion transport processes in cells. By blocking these channels, TRAM34 can inhibit the production of pro-inflammatory cytokines and reduce inflammation. Additionally, it may have neuroprotective effects by reducing the damage caused by oxidative stress and inflammation.
Product mechanism: TRAM34 works by selectively inhibiting the activity of IK channels, which are expressed in many types of cells, including immune cells, endothelial cells, and neurons. These channels play a significant role in regulating cellular calcium signaling and ion transport. By blocking the activity of IK channels, TRAM34 can reduce the production of pro-inflammatory cytokines and reduce inflammation.
Safety: While TRAM34 has shown promising results in preclinical studies, it is still undergoing testing to confirm its safety and efficacy. At present, there are no FDA-approved drugs containing TRAM34.
Side effects: As with any medication, some side effects may occur when taking TRAM34. However, it has shown good tolerability in preclinical studies, with most adverse effects being mild to moderate in severity.
Dosing information: The dosage of TRAM34 will vary depending on the condition being treated, the patient's age, and other factors. Currently, there is no recommended dose for TRAM34, as it is not yet approved for medical use.
Conclusion: In conclusion, TRAM34 is a promising new product that offers significant potential health benefits for various diseases associated with inflammation and ion transport. It works by selectively inhibiting the activity of IK channels, which play a critical role in regulating cellular calcium signaling and ion transport. While more research is necessary to confirm its efficacy and safety, early studies show promise. With continued research, TRAM34 may provide valuable insights into the potential uses of IK channel inhibitors and how they can be used to improve human health
